WO1998016265B1 - Liquid embolic agents containing partially hydrolyzed polyvinyl acetate - Google Patents
Liquid embolic agents containing partially hydrolyzed polyvinyl acetateInfo
- Publication number
- WO1998016265B1 WO1998016265B1 PCT/US1997/018582 US9718582W WO9816265B1 WO 1998016265 B1 WO1998016265 B1 WO 1998016265B1 US 9718582 W US9718582 W US 9718582W WO 9816265 B1 WO9816265 B1 WO 9816265B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- occludant
- new
- precursor composition
- partially hydrolyzed
- radio
- Prior art date
Links
- 229920002689 polyvinyl acetate Polymers 0.000 title claims abstract 26
- 239000011118 polyvinyl acetate Substances 0.000 title claims abstract 26
- 230000003073 embolic Effects 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 37
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims abstract 32
- 210000003240 Portal Vein Anatomy 0.000 claims abstract 3
- 239000000463 material Substances 0.000 claims 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 16
- 239000002904 solvent Substances 0.000 claims 10
- BAQCROVBDNBEEB-KSDLJXBFSA-N 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodo-N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)O[C@@H]2O)O)=C1I BAQCROVBDNBEEB-KSDLJXBFSA-N 0.000 claims 8
- DGAIEPBNLOQYER-UHFFFAOYSA-N Iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims 8
- 229960002603 Iopromide Drugs 0.000 claims 8
- 229960000554 metrizamide Drugs 0.000 claims 8
- 210000004185 Liver Anatomy 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000014961 Protein Precursors Human genes 0.000 abstract 1
- 108010078762 Protein Precursors Proteins 0.000 abstract 1
- 230000002440 hepatic Effects 0.000 abstract 1
Abstract
This relates to a composition of matter comprising partially hydrolyzed polyvinyl acetate solutions suitable for use as embolic agent precursors. In addition, a procedure for introducing the solutions into the human body to form precipitated embolic occlusion masses is shown. Finally, a procedure for treatment of hepatic tumors using portal vein embolism is described.
Claims
1. An occludant precursor composition for forming an occlusion mass upon introduction of the precursor into a mammalian body comprising a solution of: a.) partially hydrolyzed polyvinylacetate, b.) a pharmaceutically acceptable solvent, and c.) a soluble radio-opaque material.
2. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10.000 to 500,000.
3. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50.000 to 100,000.
4. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
5. The occludant precursor composition of claim 1 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.3 to 5.6.
6. The occludant precursor composition of claim 5 wherein the composition contains between 7.5 and 30%(wt) of partially hydrolyzed polyvinylacetate.
20
7. The occludant precursor composition of claim 1 wherein the pharmaceutically acceptable solvent comprises ethanol.
8. The occludant precursor composition of claim 1 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution.
9. The occludant precursor composition of claim 1 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution containing 30 to 55%(vol) ethanol.
10. The occludant precursor composition of claim 9 wherein the aqueous ethanolic solution contains 45-55% (vol) ethanol.
1 1. [cancelled]
12. The occludant precursor composition of claim 1 wherein the radio-opaque material comprises a material selected from the group consisting of iopromide. metrizamide, and mixtures and solutions thereof.
13. The occludant precursor composition of claim 12 wherein the radio-opaque material comprises iopromide.
14. The occludant precursor composition of claim 12 wherein the radio-opaque material comprises metrizamide.
15. A method for occluding a selected site in a mammalian body comprising the steps of: a.) introducing to said selected site an occludant precursor composition for forming an occlusion mass, said precursor comprising a solution of: i) partially hydrolyzed polyvinylacetate. [and] ii.) a pharmaceutically acceptable solvent, iii.) a soluble radio-opaque material, and b.) releasing said occludant precursor composition at said selected site to form said occlusion mass.
16. The method of claim 15 wherein the introducing step is carried out using a tubular member.
17. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10,000 to 500,000.
18. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50,000 to 100.000.
19. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
20. The method of claim 15 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.3 to 5.6.
22
21. The method of claim 15 wherein the composition contains between 7.5 and 30%(wf) of partially hydrolyzed polyvinylacetate.
22. The method of claim 15 wherein the pharmaceutically acceptable solvent comprises ethanol.
23. The method of claim 15 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution.
24. The method of claim 15 wherein the pharmaceutically acceptable solvent comprises an aqueous ethanolic solution containing 30 to 55%(vol) ethanol.
25. The method of claim 24 wherein the aqueous ethanolic solution contains 45- 55% ethanol.
26. [cancelled]
27. The method of claim 15 wherein the radio-opaque material comprises a material selected from the group consisting of iopromide. metrizamide, and mixtures and solutions thereof.
28. The method of claim 15 wherein the radio-opaque material comprises iopromide.
23
29. The method of claim 15 wherein the radio-opaque material comprises metrizamide.
30. The method of claim 15 wherein the tubular member is passed into the portal vein proximal of the liver.
31. (new) An occludant precursor composition for forming an occlusion mass upon introduction of the precursor into a mammalian body comprising a solution of: a.) partially hydrolyzed polyvinylacetate, and b.) a pharmaceutically acceptable solvent comprising an aqueous ethanolic solution containing 30 to 55%(vol) ethanol.
32. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10,000 to 500,000.
33. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50,000 to 100.000.
34. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
35. (new) The occludant precursor composition of claim 31 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the ranee of 2.3 to 5.6.
24
36. (new) The occludant precursor composition of claim 35 wherein the composition contains between 7.5 and 30%(wt) of partially hydrolyzed polyvinylacetate.
37. (new) The occludant precursor composition of claim 31 further comprising a radio-opaque material.
38. (new) The occludant precursor composition of claim 37 wherein the radio- opaque material comprises a material selected from the group consisting of iopromide, metrizamide, and mixtures and solutions thereof.
39. (new) The occludant precursor composition of claim 37 wherein the radio- opaque material comprises iopromide.
40. (new) The occludant precursor composition of claim 37 wherein the radio- opaque material comprises metrizamide.
41. (new) A method for occluding a selected site in a mammalian body comprising the steps of: a.) introducing to said selected site an occludant precursor composition for forming an occlusion mass, said precursor comprising a solution of: i) partially hydrolyzed polyvinylacetate, and ii.) a pharmaceutically acceptable solvent comprising an aqueous ethanolic solution containing 30 to 55%(vol) ethanol, and b.) releasing said occludant precursor composition to form said occlusion mass.
42. (new) The method of claim 41 wherein the introducing step is carried out using a tubular member.
25
43. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 10,000 to 500,000.
44. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a molecular weight in the range of 50,000 to 100,000.
45. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.0 to 6.0.
46. (new) The method of claim 41 wherein the partially hydrolyzed polyvinylacetate has a ratio of acetate groups to hydrolyzed acetate sites in the range of 2.3 to 5.6.
47. (new) The method of claim 41 wherein the composition contains between 7.5 and 30%(wt) of partially hydrolyzed polyvinylacetate.
48. (new) The method of claim 41 wherein the composition further comprises a radio-opaque material.
49. (new) The method of claim 48 wherein the radio-opaque material comprises a material selected from the group consisting of iopromide. metrizamide. and mixtures and solutions thereof.
50. (new) The method of claim 48 wherein the radio-opaque material comprises iopromide.
26
51. (new) The method of claim 48 wherein the radio-opaque material comprises metrizamide.
52. (new) The method of claim 41 wherein the tubular member is passed into the portal vein proximal of the liver.
27 STATEMENT UNDER ARTICLE 19
This in response to the International Search Report mailed 3/3/98. In this Amendment, claims 1 1 and 26 have been cancelled and new claims 31 through 52 have been added. Consequently, claims 1 -10, 12-25. and 27-52 are under consideration. Reconsideration is requested.
28
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP51855298A JP3804071B2 (en) | 1996-10-17 | 1997-10-15 | Liquid embolic agent containing partially hydrolyzed polyvinyl acetate |
| EP97912731A EP0934086B1 (en) | 1996-10-17 | 1997-10-15 | Liquid embolic agents containing partially hydrolyzed polyvinyl acetate |
| DE69735534T DE69735534T2 (en) | 1996-10-17 | 1997-10-15 | LIQUID EMBOLIZING AGENTS OF PARTIALLY HYDROLYZED POLYVINYL ACETATE |
| AU49842/97A AU4984297A (en) | 1996-10-17 | 1997-10-15 | Liquid embolic agents containing partially hydrolyzed polyvinyl acetate |
| US09/291,853 US6160025A (en) | 1996-10-17 | 1999-04-14 | Liquid embolic agents |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/734,442 US5925683A (en) | 1996-10-17 | 1996-10-17 | Liquid embolic agents |
| US08/734,442 | 1996-10-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/734,442 Continuation-In-Part US5925683A (en) | 1996-10-17 | 1996-10-17 | Liquid embolic agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/291,853 Continuation US6160025A (en) | 1996-10-17 | 1999-04-14 | Liquid embolic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998016265A1 WO1998016265A1 (en) | 1998-04-23 |
| WO1998016265B1 true WO1998016265B1 (en) | 1998-06-18 |
Family
ID=24951721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/018582 WO1998016265A1 (en) | 1996-10-17 | 1997-10-15 | Liquid embolic agents containing partially hydrolyzed polyvinyl acetate |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US5925683A (en) |
| EP (1) | EP0934086B1 (en) |
| JP (1) | JP3804071B2 (en) |
| AU (1) | AU4984297A (en) |
| DE (1) | DE69735534T2 (en) |
| WO (1) | WO1998016265A1 (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063070A (en) | 1997-08-05 | 2000-05-16 | Target Therapeutics, Inc. | Detachable aneurysm neck bridge (II) |
| EP1003422B1 (en) | 1997-08-05 | 2006-06-14 | Boston Scientific Limited | Detachable aneurysm neck bridge |
| US6511468B1 (en) | 1997-10-17 | 2003-01-28 | Micro Therapeutics, Inc. | Device and method for controlling injection of liquid embolic composition |
| US6146373A (en) * | 1997-10-17 | 2000-11-14 | Micro Therapeutics, Inc. | Catheter system and method for injection of a liquid embolic composition and a solidification agent |
| WO2000013593A1 (en) | 1998-09-04 | 2000-03-16 | Boston Scientific Limited (Incorporated In Ireland) | Detachable aneurysm neck closure patch |
| FR2784580B1 (en) | 1998-10-16 | 2004-06-25 | Biosepra Inc | POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME |
| WO2001003666A2 (en) * | 1999-07-12 | 2001-01-18 | Scimed Life Systems, Inc. | Liquid based vaso-occlusive compositions |
| US6346098B1 (en) | 2000-03-07 | 2002-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and kits for locally administering an active agent to an interstitial space of a host |
| CA2403218C (en) | 2000-03-13 | 2011-10-18 | Biocure, Inc. | Embolic compositions |
| DE01918975T1 (en) * | 2000-03-24 | 2006-04-13 | Biosphere Medical, Inc., Rockland | Microspheres for active embolization |
| US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| US6729356B1 (en) | 2000-04-27 | 2004-05-04 | Endovascular Technologies, Inc. | Endovascular graft for providing a seal with vasculature |
| US6658288B1 (en) | 2000-05-05 | 2003-12-02 | Endovascular Technologies, Inc. | Apparatus and method for aiding thrombosis through the application of electric potential |
| DE10117099A1 (en) * | 2000-08-02 | 2002-02-21 | Aesculap Ag & Co Kg | Medical technology product, process for its production and provision for surgery |
| WO2002009789A2 (en) * | 2000-08-02 | 2002-02-07 | Aesculap Ag & Co. Kg | Medical technical product, method for producing the same and providing the same for surgery |
| US20020165582A1 (en) * | 2001-04-26 | 2002-11-07 | Porter Christopher H. | Method and apparatus for delivering materials to the body |
| US20020193812A1 (en) * | 2001-05-04 | 2002-12-19 | Concentric Medical | Hydrogel vaso-occlusive device |
| EP1392175A2 (en) * | 2001-05-04 | 2004-03-03 | Concentric Medical | Hydrogel filament vaso-occlusive device |
| WO2002089865A2 (en) * | 2001-05-04 | 2002-11-14 | Concentric Medical | Coated combination vaso-occlusive device |
| US6685745B2 (en) | 2001-05-15 | 2004-02-03 | Scimed Life Systems, Inc. | Delivering an agent to a patient's body |
| US7687053B2 (en) * | 2001-08-20 | 2010-03-30 | Boston Scientific Scimed, Inc. | Embolic compositions with non-cyanoacrylate rheology modifying agents |
| US20030050635A1 (en) * | 2001-08-22 | 2003-03-13 | Csaba Truckai | Embolization systems and techniques for treating tumors |
| US6911219B2 (en) * | 2001-09-27 | 2005-06-28 | Surgica Corporation | Partially acetalized polyvinyl alcohol embolization particles, compositions containing those particles and methods of making and using them |
| US20030093111A1 (en) * | 2001-10-26 | 2003-05-15 | Concentric Medical | Device for vaso-occlusion and interventional therapy |
| US7341716B2 (en) * | 2002-04-12 | 2008-03-11 | Boston Scientific Scimed, Inc. | Occlusive composition |
| WO2004039425A1 (en) * | 2002-10-29 | 2004-05-13 | Toray Industries, Inc. | Vascular embolization meterial |
| HUP0203719A2 (en) * | 2002-10-31 | 2007-09-28 | Stepan Dr Gudak | Polyuretan composition for fillin blood vessels and method of aplication of it |
| US20040115164A1 (en) * | 2002-12-17 | 2004-06-17 | Pierce Ryan K. | Soft filament occlusive device delivery system |
| EP1601392B1 (en) * | 2003-03-07 | 2009-04-29 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels comprising high levels of contrast agent |
| US20050209674A1 (en) * | 2003-09-05 | 2005-09-22 | Kutscher Tuvia D | Balloon assembly (V) |
| US20050090804A1 (en) * | 2003-10-22 | 2005-04-28 | Trivascular, Inc. | Endoluminal prosthesis endoleak management |
| US20050283182A1 (en) * | 2004-06-21 | 2005-12-22 | Concentric Medical, Inc. | Systems and methods for intraluminal delivery of occlusive elements |
| BRPI0608766A8 (en) | 2005-05-09 | 2018-04-17 | Biosphere Medical Sa | substantially spherical microsphere, composition, and methods for drug delivery and active embolization in a mammal |
| JP2009512515A (en) * | 2005-10-19 | 2009-03-26 | パルサー バスキュラー インコーポレイテッド | Methods and systems for clipping within a vessel and repairing intraluminal and tissue defects. |
| US8545530B2 (en) * | 2005-10-19 | 2013-10-01 | Pulsar Vascular, Inc. | Implantable aneurysm closure systems and methods |
| US20080039890A1 (en) * | 2006-01-30 | 2008-02-14 | Surgica Corporation | Porous intravascular embolization particles and related methods |
| EP1986707A2 (en) * | 2006-01-30 | 2008-11-05 | Surgica Corporation | Compressible intravascular embolization particles and related methods and delivery systems |
| US7442105B2 (en) * | 2006-05-05 | 2008-10-28 | Freleng Safety Products, Llc | Personal visibility marker |
| US20080255678A1 (en) * | 2007-04-13 | 2008-10-16 | Cully Edward H | Medical apparatus and method of making the same |
| US9642693B2 (en) * | 2007-04-13 | 2017-05-09 | W. L. Gore & Associates, Inc. | Medical apparatus and method of making the same |
| US9717584B2 (en) * | 2007-04-13 | 2017-08-01 | W. L. Gore & Associates, Inc. | Medical apparatus and method of making the same |
| EP3903696A1 (en) * | 2008-09-05 | 2021-11-03 | Pulsar Vascular, Inc. | Systems and methods for supporting or occluding a physiological opening or cavity |
| US20110212179A1 (en) * | 2008-10-30 | 2011-09-01 | David Liu | Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same |
| EP2805680B1 (en) | 2009-09-04 | 2017-10-25 | Pulsar Vascular, Inc. | Systems for enclosing an anatomical opening |
| EP2713905B1 (en) | 2011-06-03 | 2022-03-16 | Pulsar Vascular, Inc. | Systems for enclosing an anatomical opening, including shock absorbing aneurysm devices |
| WO2012167156A1 (en) | 2011-06-03 | 2012-12-06 | Pulsar Vascular, Inc. | Aneurysm devices with additional anchoring mechanisms and associated systems and methods |
| EP3738527A1 (en) | 2011-10-05 | 2020-11-18 | Pulsar Vascular, Inc. | Devices for enclosing an anatomical opening |
| US9259229B2 (en) | 2012-05-10 | 2016-02-16 | Pulsar Vascular, Inc. | Systems and methods for enclosing an anatomical opening, including coil-tipped aneurysm devices |
| CN102764456B (en) * | 2012-07-24 | 2014-10-15 | 上海交通大学 | Vascular occlusive agent, application thereof and preparation method |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2160503A (en) * | 1936-02-14 | 1939-05-30 | Chemische Forschungs Gmbh | Blood stancher |
| US2657201A (en) * | 1949-11-25 | 1953-10-27 | Du Pont | Controlled, heterogeneous hydrolysis of polymeric esters |
| CA935153A (en) * | 1969-06-27 | 1973-10-09 | Nyegaard And Co. A/S | 2,4,6-triiodobenzoyl amines used as x-ray contrast agents |
| DE2909439A1 (en) * | 1979-03-08 | 1980-09-18 | Schering Ag | NEW NON-ionic x-ray contrast agents |
| US4631188A (en) * | 1983-08-31 | 1986-12-23 | S.K.Y. Polymers, Ltd. (Kingston Technologies) | Injectable physiologically-acceptable polymeric composition |
| US4739768B2 (en) * | 1986-06-02 | 1995-10-24 | Target Therapeutics Inc | Catheter for guide-wire tracking |
| GB8900376D0 (en) * | 1989-01-09 | 1989-03-08 | Nycomed As | Iodinated esters |
| EP0470569B1 (en) * | 1990-08-08 | 1995-11-22 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis inhibiting substance |
| US5690666A (en) * | 1992-11-18 | 1997-11-25 | Target Therapeutics, Inc. | Ultrasoft embolism coils and process for using them |
| US5443454A (en) * | 1992-12-09 | 1995-08-22 | Terumo Kabushiki Kaisha | Catheter for embolectomy |
| CA2197679C (en) * | 1994-08-17 | 2007-09-11 | Patrik Luescher | Implant, and method and device for inserting the implant |
| US5749894A (en) * | 1996-01-18 | 1998-05-12 | Target Therapeutics, Inc. | Aneurysm closure method |
| US5702361A (en) * | 1996-01-31 | 1997-12-30 | Micro Therapeutics, Inc. | Method for embolizing blood vessels |
-
1996
- 1996-10-17 US US08/734,442 patent/US5925683A/en not_active Expired - Lifetime
-
1997
- 1997-10-15 AU AU49842/97A patent/AU4984297A/en not_active Abandoned
- 1997-10-15 JP JP51855298A patent/JP3804071B2/en not_active Expired - Fee Related
- 1997-10-15 DE DE69735534T patent/DE69735534T2/en not_active Expired - Lifetime
- 1997-10-15 EP EP97912731A patent/EP0934086B1/en not_active Expired - Lifetime
- 1997-10-15 WO PCT/US1997/018582 patent/WO1998016265A1/en active IP Right Grant
-
1999
- 1999-04-14 US US09/291,853 patent/US6160025A/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998016265B1 (en) | Liquid embolic agents containing partially hydrolyzed polyvinyl acetate | |
| DE69826452T2 (en) | LOCAL SPECIFIC PROTEIN MODIFICATION | |
| WO1996007398A3 (en) | Sustained release of peptides from pharmaceutical compositions | |
| EP0386960A3 (en) | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings | |
| CA2212856A1 (en) | Benzopyran-containing compounds and method for their use | |
| DE3481170D1 (en) | NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND METHOD FOR THE PRODUCTION THEREOF. | |
| TW329386B (en) | Cough medicine | |
| JPH05503940A (en) | Novel insulin composition | |
| Chatt et al. | Chemical evidence concerning the function of molybdenum in nitrogenase | |
| WO1996012505A1 (en) | Conjugates of a polypeptide or oligopeptide with a low molecular weight lipophilic compound | |
| CA2085469A1 (en) | Water-soluble polypeptides with strong affinity for .alpha. and .beta. interferons | |
| HU9202044D0 (en) | Method for producing 4-phenyl-piperidine-4-carbixamide derivatives and pharmaceutical preparatives containing these compounds as active agents | |
| CA2362652A1 (en) | Coating composition and method for producing the same | |
| WO1996001634B1 (en) | Long-acting oxytetracycline composition | |
| EP0383346A3 (en) | Catalyst, process for its preparation and process for polymerization of olefins using this catalyst | |
| GB1587663A (en) | Iodinated isophthalamic acid derivatives | |
| IE51657B1 (en) | Lh-rh antagonists | |
| Colonna et al. | Large scale HELP synthesis of oligodeoxynucleotides by the hydroxybenzotriazole phosphotriester approach. | |
| WO1999005103A3 (en) | 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent | |
| US4368138A (en) | Water soluble thymidine derivative | |
| WO2001032680A3 (en) | 18-nor-steroids as selectively active estrogens | |
| EP0387090A3 (en) | Steroid derivatives,processes for their preparation and pharmaceutical compositions thereof | |
| EP0365139A3 (en) | Bile acids for the treatment of viral infections | |
| JP3898850B2 (en) | Gelling agent comprising sugar derivative having metal coordination ability | |
| AU4545289A (en) | 2-azabicyclo(2.2.1)hept-5-ene-2-acetic acid, derivatives thereof and related compounds, process for the preparation of said compounds and the use of said compounds for the manufacture of n-phosphonomethylglycine |